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Treatment
Heart failure (HF) is a shared chronic phase of many cardiac 
diseases, including ischaemic heart disease, chronic obstructive 
pulmonary disease and hypertension. It is characterised by structural 
or functional impairment of ventricular filling or ejection of blood from 
the heart.1–3 It is estimated that there are more than 37.7 million cases 
of HF globally and its prevalence is on the rise.2 HF can be categorised 
into two subtypes: HF with reduced ejection fraction (HFrEF), defined by 
guidelines as an ejection fraction ≤40%, and HF with preserved ejection 
fraction (HFpEF), defined as an ejection fraction ≥50%, with those falling 
between these ranges considered to have borderline HFpEF or 
mid‑range ejection fraction.3,4 
Treatment options for HFrEF include combining angiotensin‑converting 
enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) with 
mineralocorticoid receptor antagonists (MRAs), beta‑blockers or diuretics 
as needed.3 The evidence for the efficacy of these treatments in HFrEF 
was published in the early 1990s and 2000s; since this time, the only 
treatment to demonstrate a benefit for patients with HFrEF has been the 
angiotensin receptor neprilysin inhibitor (ARNI) sacubitril–valsartan, 
which reported superiority to ACE inhibition in reducing the risks of death 
and hospitalisation for HF in 2014.5 Disappointingly, the vast majority of 
trials in patients with HFpEF have failed to demonstrate robust efficacy. 
The much‑anticipated Efficacy and Safety of LCZ696 Compared to 
Valsartan, on Morbidity and Mortality in Heart Failure Patients With 
Preserved Ejection Fraction (PARAGON‑HF) trial of sacubitril–valsartan in 
patients with HFpEF missed its primary endpoint, although there were 
some indicators of efficacy in specific patient subgroups, meaning that 
patients with HFpEF still have very few treatment options with 
demonstrated benefit in hospitalisation and mortality.6 
The US Food and Drug Administration (FDA) has recently approved the 
sodium–glucose co‑transporter 2 (SGLT2) inhibitor dapagliflozin for the 
treatment of patients with HFrEF.7 Originally developed to aid glycaemic 
control in type 2 diabetes (T2D), dapagliflozin has the potential to 
substantially improve outcomes for HFrEF patients. This approval 
follows the release of data from the groundbreaking Study to Evaluate 
the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure 
or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA‑
HF) trial, which was the first large‑scale trial to demonstrate the efficacy 
of an SGLT2 inhibitor in a patient population that included both those 
with and without T2D.8 More recently, the Empagliflozin Outcome Trial in 
Patients With Chronic Heart Failure With Reduced Ejection Fraction 
(EMPEROR‑Reduced) trial investigating another SGLT2 inhibitor, 
empagliflozin, in patients with HFrEF also reported reductions in 
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hospitalisation for HF, but failed to demonstrate benefit in terms of 
mortality.9
This article aims to discuss the evidence supporting the use of 
dapagliflozin and empagliflozin in patients with HFrEF with and without 
T2D and the optimal place for SGLT2 inhibitors in HF therapy.
The Impact of SGLT2 Inhibition on Cardiovascular 
Outcomes in Type 2 Diabetes Patients
T2D is a major cardiovascular (CV) risk factor; CV disease (CVD) affects 
around one‑third of people with T2D and is a major cause of mortality.10 
Amid this background of increased CV risk, and following concerns 
surrounding the CV safety profile of the thiazolidinedione rosiglitazone, 
the FDA and European Medicines Agency issued guidance requiring 
sponsors to investigate the CV safety profiles of new glucose‑lowering 
drugs through CV outcomes trials (CVOTs).11 Unexpectedly, rather than 
simply providing assurance surrounding the CV safety of SGLT2 
inhibitors, results from three large‑scale trial programmes in T2D 
suggested that these therapies could prevent serious CV events.12 
In 2015, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients (EMPA‑REG OUTCOME) was the first trial to 
demonstrate that treatment with an SGLT2 inhibitor significantly 
reduced the rate of CV events compared with placebo in patients with 
T2D and established CVD.13 The trial reported a significant reduction in 
the primary outcome, a composite of death from CV causes, non‑fatal 
MI or non‑fatal stroke in the empagliflozin group compared with 
placebo (10.5% versus 12.1%; HR 0.86; 95% CI [0.74–0.99]; p<0.001 for 
non‑inferiority and p=0.04 for superiority).13 The outcome was primarily 
driven by CV death, with rates of 3.7% in the empagliflozin versus 5.9% 
in the placebo groups (p<0.001). Rates of all MI (4.8% versus 5.4%; 
p=0.23) and all stroke (3.5% versus 3.0%; p=0.26) did not differ 
significantly between treatment groups. Subsequently, the Canagliflozin 
Cardiovascular Assessment Study (CANVAS) programme, consisting of 
sister randomised controlled trials CANVAS and CANVAS‑Renal 
(CANVAS‑R), demonstrated similar outcomes in terms of CV events, 
also in patients with T2D, the majority of whom had established CVD.14 
Both trials demonstrated substantial improvements in the rates of 
hospitalisation for HF for the investigational treatment versus placebo 
(35% reduction compared with placebo, HR 0.65; 95% CI [0.50–0.85]; 
p=0.002 in EMPA‑REG OUTCOME, and 33% reduction compared with 
placebo, HR 0.67; 95% CI [0.52–0.91] in the CANVAS programme).13,14 
Following the disclosure of these trial results, the protocol of the 
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence 
of Cardiovascular Events (DECLARE‑TIMI 58) trial was amended to 
include a composite of hospitalisation for HF and CV death as a co‑
primary endpoint. DECLARE‑TIMI 58 reported a significant reduction in 
this co‑primary endpoint (HR 0.83; 95% CI [0.73–0.95]; p=0.005), driven 
primarily by a lower rate in hospitalisation for HF (27% reduction 
compared with placebo, HR 0.73; 95% CI [0.61–0.88]).15 There was a non‑
significant numerical reduction in the second primary endpoint (CV 
death, MI or stroke).15 This was speculated to be due to the lower overall 
rate of CV events in the study population, the majority of whom (59.5%) 
had multiple CVD risk factors but not established CVD, when compared 
with the populations recruited for the other SGLT2 inhibitor CVOTs.15
In addition to the CVOTs, the renal outcomes trial Evaluation of the 
Effects of Canagliflozin on Renal and Cardiovascular Outcomes in 
Participants With Diabetic Nephropathy (CREDENCE), investigating the 
efficacy of canagliflozin in patients with diabetic nephropathy, also 
reported a substantial reduction in terms of a composite of 
hospitalisation for HF and CV death (HR 0.69; 95% CI [0.57–0.83]; 
p<0.001) and hospitalisation for HF (HR 0.61; 95% CI [0.47–0.80]; 
p<0.001) for patients treated with canagliflozin compared with those 
receiving placebo.16 
Meta‑analyses of CVOTs reported that SGLT2 inhibitors, as a class, 
reduced the risk of hospitalisation for HF by 31–32% in patients with 
T2D, and that this risk reduction was consistent in patients with and 
without recognised CVD (~30% reduction in risk of hospitalisation for 
HF in both subgroups).12,17 Furthermore, they demonstrated that the 
event reductions were similar in comparable patient populations 
(Figure 1). 
Figure 1: Impact of SGLT2 Inhibition on Cardiovascular Disease Endpoints in Patients with Type 2 Diabetes
MACE HHF
Favours treatment Favours placebo
0 0.5 1 1.5
Favours treatment Favours placebo
0 0.5 1 1.5
Established ASCVD HR [95% CI] Established ASCVD HR [95% CI]
EMPA-REG OUTCOME 0.86 [0.74–0.99] EMPA-REG OUTCOME 0.65 [0.50–0.85]
CANVAS 0.82 [0.72–0.95] CANVAS 0.68 [0.51–0.90]
DECLARE-TIMI 58 0.90 [0.79–1.02] DECLARE-TIMI 58 0.78 [0.63–0.97]
FE model for ASCVD 0.86 [0.80–0.93] FE model for ASCVD 0.71 [0.62–0.82]
Multiple risk factors Multiple risk factors
EMPA-REG OUTCOME No MRF patients EMPA-REG OUTCOME No MRF patients
CANVAS 0.98 [0.74–1.30] CANVAS 0.64 [0.32–1.15]
DECLARE-TIMI 58 1.01 [0.86–1.20] DECLARE-TIMI 58 0.64 [0.46–0.88]
FE model for MRF 1.00 [0.87–1.16] FE model for MRF 0.64 [0.48–0.85]
ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; HHF = hospitalisation for heart failure; FE = fixed effects; MACE = major adverse cardiovascular events; 
MRF = multiple risk factors; SGLT2 = sodium–glucose co-transporter 2; T2D = type 2 diabetes. Source: Zelniker et al. 2019.12 Reproduced with permission from Elsevier.
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Subgroup analyses of EMPA‑REG OUTCOME and DECLARE‑TIMI 58 
demonstrated consistent benefit on the composite of hospitalisation 
for HF or CV death, irrespective of baseline HF status.15,18 Results from 
an equivalent analysis of the CANVAS programme suggested that the 
benefit of canagliflozin on the composite of hospitalisation for HF and 
CV death may have been more pronounced in those with a prior 
history of HF compared with those without (p interaction = 0.021). 
However, all other outcomes were similar between the subgroups 
(Figure 2).19 A meta‑analysis of EMPA‑REG OUTCOME, DECLARE‑TIMI 
58 and the CANVAS programme reported similar benefits for patients 
with and without a history of HF, with low heterogeneity between 
interventions.12
SGLT2 Inhibitors in Patients with HFrEF
Limited additional post-hoc analyses provided more insights on the 
impact of SGLT2 inhibitors by HF subtype. An analysis of the CANVAS 
programme found that canagliflozin reduced the overall risk of HFrEF 
(ejection fraction <50%) events leading to hospitalisation or death (HR 
0.69; 95% CI [0.48–1.00]).20 Ejection fraction classification for patients 
with a history of HF was not required at baseline within the CANVAS 
programme, and this analysis was not restricted to those with a history 
of HF, resulting in a limited application of these results for those with a 
history of HF specifically.20 A post-hoc analysis of DECLARE‑TIMI 58, 
which collected more complete baseline data, found a 36% risk 
reduction for hospitalisation for HF, a 45% risk reduction for CV death 
and a 51% risk reduction in all‑cause death in patients with a history of 
HFrEF (known ejection fraction <45%).21 These subgroup analyses, 
although suggestive of the potential benefits of SGLT2 inhibitors for 
patients with HFrEF, are difficult to interpret owing to low patient 
numbers: only 10–14% of patients reported prior HF at baseline across 
the SGLT2 inhibitor CVOTs.13–15 Additionally, as well as the limitation of 
incomplete classification of HF subtypes, these trials only included 
patients with T2D (Figure 2).20,21 Dedicated studies were needed to 
confirm the signals observed in SGLT2 inhibitor CVOTs and to investigate 
whether these benefits extend to patients with HF without T2D.
The DAPA-HF Trial
DAPA‑HF was the first outcomes trial of an SGLT2 inhibitor to investigate 
the treatment of HF in patients with HFrEF with and without T2D.8 
DAPA‑HF was a multicentre Phase III placebo‑controlled clinical trial in 
4,744 patients with New York Heart Association class II, III or IV HF and 
ejection fraction ≤40%. Patients were required to have a plasma level of 
N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP) ≥600 pg/ml 
(≥400 pg/ml if they had been hospitalised for HF within the previous 12 
months and ≥900 pg/ml if they had AF or atrial flutter on baseline ECG). 
Exclusion criteria were recent treatment with, or intolerance to, an 
SGLT2 inhibitor, type 1 diabetes, systolic blood pressure <95 mmHg, an 
estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2, or 
rapidly declining renal function. Patients received dapagliflozin 10 mg 
once daily or placebo, and were required to receive standard best‑
practice HF device and drug therapy, including an ACE inhibitor, an ARB, 
or sacubitril–valsartan plus a beta‑blocker, unless contraindicated.8
Figure 2: Number and Clinical Categorisation of Patients With Prior HF in 





































Each n is the number of patients with reported prior diagnosis of HF within each trial. *SOLOIST-WHF trial was terminated early due to financial concerns; data from the final analysis is pending. 
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HFpEF = heart failure with preserved ejection fraction; SGLT2 = sodium–glucose co-transporter 2; T2D = type 2 diabetes. 
Source: Zinman et al. 2015,13 Neal et al. 2017,14 Wiviott et al. 2019,15 Perkovic et al. 2019,16 McMurray et al. 2019,8 NCT03057977, NCT03521934, NCT03057951 and NCT03619213.
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At baseline, 45% of patients had T2D and 55% did not. Baseline therapies 
were similar between groups, with 93.4% and 93.5% receiving a diuretic, 
71.5% and 70.6% receiving MRAs, 56.1% receiving an ACE inhibitor, 
28.4% and 26.7% receiving an ARB, 10.5% and 10.9% receiving 
sacubitril–valsartan, and 96.0% and 96.2% receiving a beta‑blocker, for 
dapagliflozin and placebo groups, respectively. The majority of patients 
were men (76.2% in the dapagliflozin group and 77% in the placebo 
group).8 Mean eGFR was 66.0 ml/min/1.73m2 in the dapagliflozin group 
and 65.5 ml/min/1.73m2 in the placebo group at baseline.
The primary outcome was a composite of worsening HF (hospitalisation 
or an urgent visit resulting in IV therapy for HF) or CV death. Over a 
median of 18.2 months, the primary outcome occurred in 386 out of 
2,373 patients (16.3%) in the dapagliflozin group and in 502 out of 
2,371 patients (21.2%) in the placebo group (HR 0.74; 95% CI [0.65–0.85]; 
p<0.001). Death from CV causes occurred in 9.6% of the dapagliflozin 
group and in 11.5% of the placebo group (HR 0.82; 95% CI [0.69–0.98]). 
During the trial period, the number of patients needed to treat to 
prevent one primary event was 21 (95% CI [15–38]). Hospitalisation for 
HF occurred in 9.7% of the dapagliflozin group and in 13.4% of the 
placebo group (HR 0.70; 95% CI [0.59–0.83]; p<0.001; Table 1).8 Both 
first and recurrent hospitalisations for HF were significantly reduced 
in the dapagliflozin group compared with placebo.22 The incidence of 
the secondary composite outcome of hospitalisation for HF or death 
from CV causes was also lower in the dapagliflozin group than in the 
placebo group (567 events versus 742 events, HR 0.74; 95% CI [0.65–
0.85]; p<0.001; Table 1). In addition, there was a 17% reduction in all‑
cause mortality (HR 0.83; 95% CI [0.71–0.97]) in the dapagliflozin arm 
of DAPA‑HF compared to placebo.8 A 29% reduction in the worsening 
of renal function, which was not statistically significant (HR 0.71; 95% 
CI [0.44–1.16]), was also observed in the dapagliflozin arm.8 Overall 
numbers of renal progression events were low in DAPA‑HF, with 
40.6% of patients having impaired renal function (eGFR between ≥30 
ml/min/1.73m2 and <60 ml/min/1.73m2), but the relative reduction 
observed in the dapagliflozin arm was similar to renal composite 
results for patients with T2D from DECLARE‑TIMI 58.15 
Moreover, recent results from DAPA‑CKD, the first dedicated renal 
outcomes trial assessing the efficacy and safety of an SGLT2 inhibitor in 
patients with chronic kidney disease with and without T2D, supported 
the renoprotective effects of dapagliflozin in patients with impaired 
renal function (eGFR ≥25 ml/min/1.73 m2 and ≤75 ml/min/1.73 m2). 
Dapagliflozin treatment was associated with a 39% reduction in renal 
function decline (HR 0.61; 95% CI [0.51–0.72]; p<0.001) and a 31% 
reduction in all‑cause death (HR 0.69; 95% CI [0.53–0.88]; p=0.004) 
compared to placebo in this patient population.23
Subgroup analyses from DAPA‑HF, both prespecified and post-hoc, 
demonstrated similar effects of dapagliflozin compared with placebo 
regardless of diuretic, MRA or ARNI use in patients who received ≥50% of 
target ACE inhibitor/ARB or beta‑blocker dose as well as those who did 
not, suggesting that treatment with dapagliflozin is beneficial regardless 
of baseline HFrEF therapy.24 Similar treatment benefits of dapagliflozin 
over placebo were also observed, irrespective of the underlying cause of 
HF, baseline renal function (eGFR <60 ml/min/1.73m2 versus eGFR ≥60 
ml/min/1.73 m2),8 systolic blood pressure,8,25 BMI,8,26 or NT‑pro‑BNP 
concentration.27 Dapagliflozin was also found to reduce the risk of death 
and worsening HF and to improve symptoms across a broad spectrum of 
age (range 22–94 years; mean age 66.3 years [SD 10.9]).28
In addition to major clinical events, DAPA‑HF also used the Kansas City 
Cardiomyopathy Questionnaire (KCCQ) patient‑reported outcome 
measure to assess HF symptom burden from the patients’ perspective. 
A clinically meaningful ≥5‑point improvement from baseline to 8 
months was reported in 58.3% of dapagliflozin‑treated patients versus 
50.9% of placebo‑treated patients (OR 1.15; 95% CI [1.08–1.23]; 
p<0.001). The number needed to treat for one patient experiencing a 
≥5‑point KCCQ improvement was 14.8 Moderate (≥10 points) and large 
(≥15 points) improvements were also more likely in the dapagliflozin 
group compared with placebo (OR 1.15; 95% CI [1.08–1.22] and OR 1.14; 
95% CI [1.08–1.22], respectively).29 There was also less deterioration in 
KCCQ score from baseline to 8 months in the dapagliflozin group than 
in the placebo group (25.3% and 32.9%, respectively; OR 0.84; 95% CI 
[0.78–0.90]; p<0.001).8 A recent post-hoc analysis also demonstrated 
that dapagliflozin reduced CV death and worsening HF across the 
range of baseline KCCQ scores (p heterogeneity = 0.52).29
Dapagliflozin was well tolerated and the rate of treatment discontinuation 
was low. The rates of serious adverse events related to volume depletion 
were slightly lower in the dapagliflozin group compared with placebo 
(1.2% and 1.7%, respectively; p=0.23), and the rate of serious renal 
adverse events was significantly lower in dapagliflozin‑treated patients 
than those receiving placebo (1.6% and 2.7%, respectively; p=0.009).8 
There had been concern that the use of dapagliflozin might lead to 
Table 1: Summary of Heart Failure Outcomes in SGLT2 Inhibitor Clinical Studies
Outcome Meta-analysis of SGLT2 Inhibitors in T2D CVOTs 
(Empagliflozin, Canagliflozin and Dapagliflozin)17




History of HF (n=4,543) HFrEF (n=4,744) HFrEF (n=3,700)
Relative risk reduction (%)
HHF 32 31 30 30
HHF and CV death 24 27 26 25
HR
HHF 0.68 (95% CI [0.60–0.76]; 
p<0.001)
0.69 (95% CI [0.57–0.83]; 
p<0.001)
0.70 (95% CI 
[0.59–0.83]; p<0.001)
0.70 (95% CI [0.58–0.85]; 
p<0.001)
HHF and CV death 0.76 (95% CI [0.63–0.84]; 
p<0.001)
0.73 (95% CI [0.63–0.84]; 
p<0.001)
0.74 (95% CI 
[0.65–0.85]; p<0.001)
0.75 (95% CI [0.65–0.86]; 
p<0.001)
CV = cardiovascular; CVOT = cardiovascular outcomes trial; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HHF = hospitalisation for heart failure; SGLT2 = sodium–
glucose co-transporter 2; T2D = type 2 diabetes. Source: Arnott et al. 2020,17 McMurray et al. 20198 and Packer et al. 2020.9
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hypoglycaemia in patients without T2D. However, major hypoglycaemic 
episodes were extremely rare and equal (0.2%) in both the dapagliflozin 
and placebo groups.8 There were no issues with ketoacidosis and no 
other significant safety concerns were reported,8 even in elderly 
individuals.28 Unlike other SGLT2 inhibitors, dapagliflozin did not increase 
the risk of fractures or amputations.
Effect of Dapagliflozin in HFrEF Patients 
with and without Type 2 Diabetes
At baseline, 42% of patients in DAPA‑HF had T2D, and an additional 3% 
received a new diagnosis of T2D during the course of the trial, resulting 
in a total of 2,139 (45%) patients with T2D.8 The reduction in the rate of 
the primary outcome was very similar between patients with T2D at 
baseline (HR 0.75; 95% CI [0.63–0.90]) and those without T2D at baseline 
(HR 0.73; 95% CI [0.60–0.88]), although the overall risk of events was 
higher in the T2D group, as expected.8,30 Similar benefits were observed 
across secondary outcomes, including risk reductions of total 
hospitalisation for HF and CV death of 23% (HR 0.77; 95% CI [0.63–0.94]) 
for patients with baseline T2D, and 27% (HR 0.73; 95% CI [0.59–0.91]) for 
those without T2D at baseline for dapagliflozin compared with placebo.30 
The DEFINE-HF Trial
The Dapagliflozin Effects on Biomarkers, Symptoms, and Functional 
Status in Patients with HF with Reduced Ejection Fraction (DEFINE‑HF) 
was a small trial of 263 patients with HFrEF, eGFR ≥30 ml/min/1.73m2 
and elevated natriuretic peptides.31 Patients were randomised to receive 
either 10 mg dapagliflozin or placebo in addition to optimal medical 
therapy for 12 weeks. The dual primary outcomes were mean NT‑proBNP 
and the proportion of patients with ≥5‑point increase in the KCCQ 
Overall Summary Score (KCCQ‑OSS) or a ≥20% decrease in NT‑proBNP. 
Although there was no significant difference in average‑adjusted NT‑
proBNP at 6 and 12 weeks, more patients in the dapagliflozin group than 
in the placebo group met the second dual primary outcome of clinically 
meaningful improvement in quality of life as measured by KCCQ‑OSS or 
a reduction of ≥20% in NT‑proBNP (61.5% versus 50.4%; p=0.039). This 
was attributable to both higher proportions of patients with a ≥5‑point 
improvement in KCCQ‑OSS (42.9% versus 32.5%; adjusted OR 1.73; 95% 
CI [0.98–3.05]; p=not significant) and with a ≥20% reduction in NT‑
proBNP (44.0% versus 29.4%; adjusted OR 1.9; 95% CI [1.1–3.3]; p=not 
significant) by 12 weeks. The results were consistent in patients with and 
without T2D, and across other prespecified subgroups including gender, 
baseline left ventricular ejection fraction and AF.31 
The EMPEROR-Reduced Trial
Results from the EMPEROR‑Reduced Phase III, placebo‑controlled 
study (NCT03057977), which involved 3,730 patients with class II, III or 
IV HF with ejection fraction ≤40% randomised to placebo or empagliflozin 
10 mg daily, added to guideline‑directed medical therapy (ACE 
inhibitors/ARBs/ARNIs, beta‐blockers and MRAs), were recently 
published.9 Plasma NT‑proBNP level required for enrolment was 
dependent on ejection fraction at baseline; ≥600 pg/ml for patients with 
ejection fraction ≤30%, ≥1,000 pg/ml for patients with ejection fraction 
31–35%, and ≥2,500 pg/ml for patients with ejection fraction 36–<40% 
(NT‑proBNP threshold was doubled for patients with AF). Exclusion 
criteria included recent treatment with, or intolerance to, an SGLT2 
inhibitor, systolic blood pressure ≥180 mmHg or <100 mmHg, eGFR <20 
ml/min/1.73m2, and impaired renal function requiring dialysis. 
Approximately half of patients had diabetes at baseline (49.8%), and 
the majority of patients were men (76.5% and 75.6% in empagliflozin 
and placebo groups, respectively). Baseline therapies were similar 
between treatment groups; 70.5% and 68.0% received an ACE 
inhibitor or ARB, 18.3% and 20.7% received sacubitril–valsartan in the 
empagliflozin and placebo groups, respectively, while 94.7% in each 
group received a beta‑blocker.9 
The primary endpoint was a time‑to‑first‑event analysis of the combined 
risk of CV death and hospitalisation for HF. After a median of 16 months, 
the primary outcome occurred in 361 of 1,863 patients (19.4%) in the 
empagliflozin group and in 462 of 1,867 patients (24.7%) in the placebo 
group (HR 0.75; 95% CI [0.65–0.86]; p<0.001; Table 1).9 This was primarily 
driven by reduced rates of hospitalisation for HF in the empagliflozin 
group (HR 0.70; 95% CI [0.58–0.85]; p<0.001; Table 1) and the trial failed 
to demonstrate a significant reduction in CV death (HR 0.92; 95% CI 
[0.75–1.12]) compared to placebo.9 There was also a significant reduction 
in the rate of renal disease progression, as measured by eGFR slope 
over time, in the empagliflozin group compared to patients receiving 
placebo (–0.55 versus –2.28 ml/min/1.73m2 per year; absolute difference 
1.73 ml/min/1.73m2 per year; 95% CI [1.10–2.37]; p<0.001).9 Unlike 
dapagliflozin in DAPA‑HF, empagliflozin failed to demonstrate efficacy in 
terms of quality of life as measured using KCCQ.9 Also, empagliflozin did 
not affect all‑cause mortality (HR 0.92; 95% CI [0.77–1.10]).9,13 
Subgroup analyses demonstrated similar effects of empagliflozin on 
the primary endpoint irrespective of baseline diabetes status (HR 0.72; 
95% CI [0.60–0.87] with diabetes; HR 0.78; 95% CI [0.64–0.97] without 
diabetes).9 Comparable treatment benefits of empagliflozin over 
placebo were also observed regardless of MRA or ARNI use, underlying 
cause of HF, or baseline renal function.9 
The adverse events profile for empagliflozin was similar to that 
reported in previous studies.9,13 The overall rates of adverse events 
and serious adverse events were lower in the empagliflozin group 
compared to the placebo group, with only genital infections reported 
substantially more frequently in the empagliflozin group (1.7%) 
compared to the placebo group (0.6%).9 As in DAPA‑HF, hypoglycaemic 
episodes of any severity were infrequent and rates were similar 
between treatment groups (1.4% versus 1.5% in empagliflozin and 
placebo groups, respectively).9 No cases of ketoacidosis were 
recorded. Although rates of fractures and amputations were slightly 
more frequent in the empagliflozin group compared to placebo (2.4% 
versus 2.3% and 0.7% versus 0.5%, respectively), the differences were 
not statistically significant.9
The EMPERIAL-Reduced Trial
The Empagliflozin Compared With Placebo On Exercise Ability and 
Heart Failure Symptoms, in Patients With Chronic Heart Failure With 
Reduced Ejection Fraction (EMPERIAL‑Reduced; NCT03448419) study 
investigated the impact of empagliflozin on exercise capacity in 312 
patients with HFrEF over 12 weeks.32 The trial did not meet its primary 
endpoint, the 6‑minute walk test, with no significant differences 
reported between the empagliflozin and placebo arms. Initial reports 
outlined substantial improvements in KCCQ total symptom score in the 
empagliflozin group compared to placebo.33 However, the results are 
yet to be published in full. 
Recent Trials of SGLT2 Inhibitors in 
HFrEF with Results Pending
Data are still awaited from some recently completed trials of SGLT2 
inhibitors treating patients with HFrEF. Dapagliflozin Effect on Exercise 
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Capacity Using a 6‑minute Walk Test in Patients With Heart Failure With 
Reduced Ejection Fraction (DETERMINE‑reduced; NCT03877237), 
investigating the impact of dapagliflozin compared to placebo on 
exercise capacity and quality of life in 313 patients with HFrEF, 
completed in March 2020 with results pending. The co‑primary 
endpoints of this study were KCCQ total symptom score, the KCCQ 
physical limitation score and 6‑minute walk test following 16 weeks of 
treatment. In addition, the Effect of Sotagliflozin on Cardiovascular 
Events in Patients With Type 2 Diabetes Post Worsening Heart Failure 
(SOLOIST‑WHF; NCT03521934) trial targeted 4,000 patients with T2D 
and HFrEF or HFpEF in the immediate post‑hospitalisation setting. In 
May 2020, the study was discontinued early because of financial 
concerns. Sotagliflozin is a dual SGLT1/SGLT2 inhibitor and thus differs 
slightly from the SGLT2 inhibitors studied to date.34 Despite the early 
closure, it is still anticipated that results from the trial will be made 
available, and it will be interesting to see whether the safety and 
efficacy of this drug replicate those observed for dapagliflozin and 
empagliflozin. 
SGLT2 Inhibitors in Patients with HFpEF
A post-hoc subgroup analysis of the CANVAS programme suggested 
that canagliflozin may reduce the rates of HFpEF (ejection fraction 
≥50%) hospitalisation or mortality events (HR 0.83; 95% CI [0.55–1.25]).20 
However, the subgroup analysis did not achieve statistical significance 
because the study was not powered to detect such a difference in this 
small subpopulation (<1% of the overall study population).20 A post-hoc 
subgroup analysis of patients with known HFpEF at baseline in the 
DECLARE‑TIMI 58 study also found a signal for reduced risk of 
hospitalisation for HF in this study population (HR 0.74; 95% CI [0.48–
1.14]), but not for CV death (HR 1.44; 95% CI [0.83–2.49]).21 Again, only 
4.7% of the total trial population of DECLARE‑TIMI 58 had a documented 
history of HFpEF; therefore, these results should be interpreted with 
caution.21 The Empagliflozin Compared With Placebo on Exercise Ability 
and Heart Failure Symptoms, In Patients With Chronic Heart Failure With 
Preserved Ejection Fraction (EMPERIAL‑Preserved; NCT03448406) trial 
investigated the impact of empagliflozin on exercise capacity in 312 
patients with HFpEF, however, found no significant difference between 
the empagliflozin and placebo groups in terms of 6‑minute walk test or 
KCCQ total symptom scores after 12 weeks.33
Two major trials of SGLT2 inhibitors in patients with HFpEF are currently 
on‑going (Figure 2). The Empagliflozin Outcome Trial in Patients With 
Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR‑
Preserved; NCT03057951) trial will follow a similar study design to the 
EMPEROR‑Reduced trial and has randomised 5,988 patients with HFpEF 
to empagliflozin or placebo.35  The study is due to be completed in 2020. 
The Dapagliflozin Evaluation to Improve the Lives of Patients With 
Preserved Ejection Fraction Heart Failure (DELIVER; NCT03619213) trial 
is aiming to recruit 6,100 patients with HFpEF, who will be randomised 
to dapagliflozin or placebo in addition to current standard therapy. The 
study is due to be completed in mid‑2021. In addition, Dapagliflozin 
Effect on Exercise Capacity Using a 6‑minute Walk Test in Patients With 
Heart Failure With Preserved Ejection Fraction (DETERMINE‑Preserved; 
NCT03877224), a randomised controlled trial investigating the impact of 
dapagliflozin compared with placebo on exercise capacity and quality 
of life in 504 patients with HFpEF, is anticipated to complete in 2020, 
and the recently discontinued SOLOIST‑WHF trial of the dual SGLT1/
SGLT2 inhibitor sotagliflozin included both patients with HFpEF and 
those with HFrEF, and may still provide some insights if sufficient data 
were collected.
Many aspects of HFpEF diagnosis and treatment remain unresolved. 
The HFpEF umbrella describes a population of patients that are very 
heterogeneous, and though there is overlap between the causes and 
risk factors for HFrEF and HFpEF, the pathophysiologies of these two 
subtypes are very distinct.36 It is hoped that the SGLT2 inhibitors will 
succeed where other drugs have failed, and the on‑going trial results 
are widely anticipated.
Mechanism of SGLT2 Inhibitors in CVD
Although originally investigated as agents for glucose management, 
SGLT2 inhibitors are now recognised to impact a wider range of systems, 
primarily in the cardio–renal axis, many of which are independent of 
glycaemic control.37–39 The SGLT2 channel is primarily located in the 
proximal tubule of the kidney, where the majority of glucose reabsorption 
takes place.40 It has been postulated that the mechanisms underlying 
SGLT2 inhibitor‑associated CV benefits could include improvements in 
ventricular load through the effect on natriuresis and osmotic diuresis 
(Figure 3).37–39 SGLT2 inhibitors have a profound effect on haemodynamics. 
Unlike diuretics, they do not deplete intravascular volume, but instead 
reduce interstitial volume.40 Optimised ventricular loading conditions, 
through reduction in preload and afterload, result in a lowering of blood 
pressure, improved endothelial function, and reduced vascular stiffness.40
It has also been suggested that SGLT2 inhibitors may improve cardiac 
metabolism and bioenergetics. The utilisation of both glucose and fatty 
acids is believed to be inefficient in the hearts of patients with HF and 
T2D. SGLT2 inhibition shifts metabolism towards the oxidation of ketone 
bodies, which has been shown to be associated with myocardial 
benefits.41 Preliminary in-vitro studies have also explored the role of 
SGLT2 inhibitors in ion exchange, cardiac remodelling and their 
influence on adipokine expression, cytokine production, and epicardial 
adipose tissue mass.40 Downstream myocardial Na+/H+ exchange 
inhibition has been shown to lead to lower levels of sodium and thus 
lower levels of calcium in cardiomyocytes, which improve contractility 
and mitochondrial function.40,42
The efficacy of dapagliflozin and empagliflozin in patients with HFrEF 
irrespective of T2D status has challenged our assumptions about the 
dominant mechanisms of action of SGLT2 inhibitors.43 Several relevant 
studies investigating the impact of SGLT2 inhibitors are currently 
underway or have recently been completed, including mechanistic 
studies of empagliflozin and dapagliflozin. The empagliflozin studies 
include: Empagliflozin in Heart Failure Patients With Reduced Ejection 
Fraction (EMPIRE‑HF; NCT03198585),44 A Study That Looks at the 
Function of the Heart in Patients With Heart Failure Who Take 
Empagliflozin (EMPA‑VISION; NCT03332212), and Empagliflozin Impact 
on Hemodynamics in Patients With Heart Failure (EMBRACE‑HF; 
NCT03030222). For dapagliflozin the studies include: Dapagliflozin in 
PRESERVED Ejection Fraction Heart Failure (PRESERVED‑HF; 
NCT03030235), A Clinical Study to Investigate the Effects of 
Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle 
Efficiency in Type 2 Diabetes Patients (DAPACARD; NCT03387683),45 
Study to Evaluate Average 24‑hr Sodium Excretion During Dapagliflozin 
Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or 
Impaired Renal Function or Non‑diabetics With Impaired Renal 
Function (DAPASALT; NCT03152084) and Effects of 5 Weeks Treatment 
With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone 
Insulin Acts on Sugar Uptake in Muscles (DAPAMAAST; NCT03338855). 
These studies are investigating the effect of SGLT2 inhibition on cardiac 
biomarkers, cardiac function, cardiac haemodynamics and 
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metabolism.44 The outcomes of this research will enable us to better 
understand how the mechanism of action of SGLT2 inhibitors directly 
influences HF outcomes in the clinical setting. 
Updating Clinical Guidelines
The importance of prevention of symptomatic HF will be a key 
consideration in current guidelines. There has also been recognition of 
the unmet need for disease‐modifying therapies that have an immediate 
impact on patient well‐being without dose‐limiting side‑effects in both 
HFrEF and HFpEF patients. SGLT2 inhibitors have been confirmed as a 
new disease‑modifying class of drug for the prevention of HF.12 
Accumulating evidence also suggests that SGLT2 inhibitors induce 
combined cardiac and renal beneficial effects in patients with HFrEF, 
and potentially HFpEF.8,9,12,23,37–41
The 2016 European Society of Cardiology (ESC) guidelines stated that 
empagliflozin should be considered in patients with T2D in order to 
prevent or delay the onset of HF (class of recommendation IIa, level of 
Figure 4: Proposed Modification to the Therapeutic Algorithm for a Patient with Symptomatic Heart Failure 
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Figure 3: Proposed Mechanism of Cardiovascular Benefits of SGLT2 Inhibitors
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Conclusion
The results from the DAPA‑HF and EMPEROR‑Reduced trials represent 
a completely new approach to HF management, strengthening the 
rationale for the use of SGLT2 inhibitors in patients with HFrEF, which 
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slow the progression of the disease. 
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both with and without T2D. Therefore, dapagliflozin should be the agent 
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